X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SANOFI INDIA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SANOFI INDIA ORCHID PHARMA LTD/
SANOFI INDIA
 
P/E (TTM) x -0.5 33.7 - View Chart
P/BV x 0.4 6.4 5.7% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 ORCHID PHARMA LTD   SANOFI INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SANOFI INDIA
Dec-16
ORCHID PHARMA LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1944,560 4.3%   
Low Rs354,400 0.8%   
Sales per share (Unadj.) Rs276.51,028.5 26.9%  
Earnings per share (Unadj.) Rs-79.2129.0 -61.4%  
Cash flow per share (Unadj.) Rs-43.5186.0 -23.4%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs53.9753.6 7.2%  
Shares outstanding (eoy) m70.4523.03 305.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.4 9.5%   
Avg P/E ratio x-1.434.7 -4.2%  
P/CF ratio (eoy) x-2.624.1 -10.9%  
Price / Book Value ratio x2.15.9 35.7%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m8,067103,174 7.8%   
No. of employees `0002.83.6 77.3%   
Total wages/salary Rs m2,5273,592 70.4%   
Avg. sales/employee Rs Th6,956.16,537.7 106.4%   
Avg. wages/employee Rs Th902.5991.4 91.0%   
Avg. net profit/employee Rs Th-1,993.0819.8 -243.1%   
INCOME DATA
Net Sales Rs m19,47723,686 82.2%  
Other income Rs m407708 57.5%   
Total revenues Rs m19,88424,394 81.5%   
Gross profit Rs m1,1035,281 20.9%  
Depreciation Rs m2,5191,313 191.9%   
Interest Rs m5,22715 34,845.3%   
Profit before tax Rs m-6,2364,661 -133.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,691 -7.4%   
Profit after tax Rs m-5,5802,970 -187.9%  
Gross profit margin %5.722.3 25.4%  
Effective tax rate %2.036.3 5.5%   
Net profit margin %-28.712.5 -228.5%  
BALANCE SHEET DATA
Current assets Rs m11,01415,673 70.3%   
Current liabilities Rs m32,0606,678 480.1%   
Net working cap to sales %-108.138.0 -284.5%  
Current ratio x0.32.3 14.6%  
Inventory Days Days9576 124.9%  
Debtors Days Days3422 150.4%  
Net fixed assets Rs m29,4408,098 363.5%   
Share capital Rs m705230 305.9%   
"Free" reserves Rs m2,04317,088 12.0%   
Net worth Rs m3,80017,356 21.9%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51025,400 183.1%  
Interest coverage x-0.2311.7 -0.1%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.9 44.9%   
Return on assets %-0.811.8 -6.5%  
Return on equity %-146.917.1 -858.2%  
Return on capital %-3.726.9 -13.9%  
Exports to sales %37.924.5 154.7%   
Imports to sales %22.628.0 80.9%   
Exports (fob) Rs m7,3785,801 127.2%   
Imports (cif) Rs m4,4066,627 66.5%   
Fx inflow Rs m7,5137,145 105.2%   
Fx outflow Rs m5,6496,846 82.5%   
Net fx Rs m1,865299 623.6%   
CASH FLOW
From Operations Rs m1,6823,226 52.1%  
From Investments Rs m-9,860-1,555 634.1%  
From Financial Activity Rs m6,644-1,818 -365.4%  
Net Cashflow Rs m-1,535-147 1,044.2%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.6 14.4 31.9%  
FIIs % 3.3 14.6 22.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.5 526.7%  
Shareholders   84,811 15,184 558.6%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  DR. DATSONS LABS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 20, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS